An analyst asked the question that was sitting in every listener’s mind. On the Q3 2026 earnings call on November 12, with revenue having fallen nearly in half from a year earlier, the exchange went to the heart of the matter: if CMS can reset DefenCath’s reimbursement rate every quarter, how does management guide for 2027? CEO Joseph Todisco’s answer was, in effect, that it cannot. CorMedix withdrew its 2027 DefenCath revenue guidance entirely, citing the new quarterly-reset methodology. Every other number on the call orbits that admission.
In one breath
CorMedix spent years as a pre-revenue biotech and turned profitable in 2025, driven by DefenCath’s launch and the Melinta acquisition. The 10-Q filed November 12 shows Q3 2026 revenue nearly cut in half from the same quarter a year ago, because a government pricing rule changed on July 1. Management reaffirmed full-year 2026 guidance but pulled its 2027 product-specific forecast. The stock sits well below where it traded twelve months ago. The math says the business is generating real cash; the mood says the market does not yet trust what that cash will look like next year.
How a company goes from zero to hundreds of millions in one year
For most of its life, CorMedix earned essentially nothing. Our data show negligible revenue in each year from 2020 through 2023, with losses compounding quietly. The turning point arrived on November 15, 2023, when the FDA approved DefenCath, a catheter-locking solution that reduces bloodstream infections in hemodialysis patients. Think of it as a rinse used between dialysis sessions to keep the catheter clean, a simple intervention in a setting where infections can be fatal.
Commercial launch followed in inpatient settings in April 2024 and outpatient dialysis clinics in July 2024. Then, in August 2025, CorMedix acquired Melinta Therapeutics, adding a portfolio of acute-care antibiotics including REZZAYO, an antifungal. The 10-K for fiscal year 2025 records the result: $312 million in revenue and a net margin of 52%, the first profitable year in the company’s history. A business that had been burning cash for a decade had, in roughly eighteen months, become one that generated more than it spent.
That context matters because the stock’s steep decline over the past twelve months is not a story about a failing business. It is a story about what happens when the pricing rule that powered the launch changes.
The cliff that arrived July 1
DefenCath’s early commercial success rested on a Medicare program called TDAPA, the Transitional Drug Add-on Payment Adjustment. TDAPA is a temporary premium that Medicare pays for newly approved drugs used in dialysis, designed to encourage adoption. It is generous by construction and, by design, temporary. On July 1, 2026, DefenCath’s TDAPA period ended.
What replaced it was a sharply lower add-on payment per dialysis session, set by CMS for the second half of 2026. The Q3 2026 10-Q shows the consequence directly: DefenCath net sales of $17.2 million for the quarter, against consolidated revenue of $54.5 million that included $31.4 million from the Melinta portfolio. A year earlier, in Q3 2025, consolidated revenue was $104.3 million. The drop is almost entirely a pricing story, not a volume story. The filing notes that outpatient dialysis customers largely maintained their utilization rates, meaning clinics kept using the product; they just paid less for it.
The underlying demand held, but the price the company receives per use fell sharply, and that gap is the whole revenue story for the quarter.
The exchange that defined the call
The withdrawal of 2027 DefenCath guidance was the sharpest moment on the November 12 call. CMS, in its October 28 ESRD final rule, established not just a new rate but a new process: the add-on payment will reset every quarter based on actual utilization data. That makes annual forecasting genuinely difficult. Management said the Q1 2027 rate would be more than triple the current rate, and that the full-year 2027 average should be at least double. But it declined to put a revenue number on that expectation, because each subsequent quarter’s rate is unknown until CMS sets it.
That is an honest answer. It is also an uncomfortable one for investors who want a number to model. The tension between those two facts explains much of the stock’s mood.
The $145 million response
Three days before the earnings call, on November 9, CorMedix announced a deal to acquire substantially all assets of Heron Therapeutics for $145 million in cash plus roughly 14.6 million common shares. The transaction is expected to close in Q1 2027. Management said the Heron assets would add between $125 million and $150 million in pro forma 2027 revenue and generate $45 million to $60 million in annualized operating cost savings by the end of 2027.
The strategic logic is straightforward: if one product’s revenue is now subject to quarterly government resets, owning more products reduces the damage any single reset can cause. Needham, revising its valuation estimate on November 10, called the Heron assets a “strategic fit” that “should help diversification to cushion volatility in DefenCath sales.” RBC Capital, maintaining an Outperform rating, moved its estimate higher on November 11. Both analysts are expressing a view; BullScope is reporting theirs, not endorsing it.
What the filing confirms is that CorMedix held $355.2 million in cash as of September 30, 2026, more than twice the cash portion of the Heron purchase price. The company can write the check without raising equity. Whether the assets it is buying justify the price is a question the filed numbers cannot yet answer, because Heron’s contribution will not appear in a CorMedix filing until after the deal closes.
What held up, what did not
Management’s full-year 2026 revenue guidance of $325 million to $345 million was reaffirmed on the call and is consistent with the quarterly revenue trend reported in the filed 10-Q. The narrowed adjusted EBITDA guidance similarly tracks the filed trend. Those numbers held up.
What did not hold up was the implicit assumption, present in earlier investor communications, that DefenCath’s post-TDAPA reimbursement would be stable enough to forecast. The new quarterly-reset mechanism, formalized in the CMS October 28 final rule, makes that impossible. Management was right to withdraw the guidance rather than invent a number; the filing’s risk disclosures now reflect that uncertainty explicitly.
One additional item from the 10-Q filed November 12 worth noting: the FDA accepted for priority review an sNDA for REZZAYO in fungal prophylaxis on October 19, 2026, with a target action date in Q1 2027. If approved, REZZAYO would expand from treatment into prevention, a larger and more recurring market. The filing records the acceptance; it cannot record the outcome.
Reading the numbers
- $54.5 million, Q3 2026 consolidated revenue (10-Q, September 30, 2026). This is what the company collected from all products in the quarter. It is roughly half of Q3 2025’s $104.3 million. Think of a shop that kept its foot traffic but cut its prices in half on its best-selling item: the customers came back, but the register rang up less.
- $17.2 million, DefenCath net sales in Q3 2026, including a $5.0 million favorable adjustment for Medicaid rebate and product return allowances. Strip that adjustment out and the underlying number is closer to $12 million. That is what a single pricing-rule change did to the company’s flagship product in one quarter.
- $2.37 to $8.32, the CMS add-on payment shift. The $2.37 rate applied per dialysis session in Q3 and Q4 2026; the $8.32 rate takes effect Q1 2027. A dialysis patient typically attends three sessions a week. At $2.37, a clinic collects roughly $7 per patient per week for using DefenCath; at $8.32, it collects roughly $25. That difference determines how attractive the product is to prescribe.
- $355.2 million in cash as of September 30, 2026. The Heron deal costs $145 million in cash. After closing, the company would hold roughly $210 million in cash, assuming no other material changes, more than enough to fund operations through the integration period.
- P/E of 2.4, against a decade median of 3.8 (our data). A multiple, in plain terms, is the price tag per dollar of profit. IF 2025’s earnings level proved repeatable and IF the multiple reverted toward its decade median of 3.8, the arithmetic would point to a materially higher price; whether either condition holds depends on the reimbursement trajectory that management itself declined to forecast. The current gap between the two multiples reflects the market’s uncertainty about earnings repeatability, not necessarily a judgment that the underlying business is impaired.
For the standing yardsticks on Cormedix: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Cormedix.
Sources
- 10-Q for quarter ended September 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- Q3 2026 earnings call transcript (Motley Fool, November 12, 2026)
- Q3 2026 financial results press release (GlobeNewswire, November 12, 2026)
- Q3 2026 earnings call summary (MarketBeat, November 12, 2026)
- Heron acquisition synergy targets (Seeking Alpha, November 2026)
- Needham and RBC valuation estimate updates (MarketBeat, November 12, 2026)
- CMS 2027 ESRD final rule and DefenCath add-on rate (Kalkine, 2026)
- CorMedix business update and 2026 guidance reaffirmation (StockTitan)
- DefenCath FDA approval (FiercePharma, November 2023)









